Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab + ALI in RRMM
NCT06880601Phase 2Not yet recruiting
- Sponsor
- GIMEMA
- Start
- Nov 2025
- Primary completion
- Nov 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of teclistamab and autologous lymphocyte infusion in multiple myeloma (MM), sponsored by GIMEMA. Primary endpoint: Duration of Response at 24 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
teclistamabautologous lymphocyte infusion
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06880601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880601.